Grimes D A, Steele A O, Hatcher R A
South Med J. 1983 Jun;76(6):743-5, 749. doi: 10.1097/00007611-198306000-00017.
Patients with obstetric hemorrhage from placenta previa or abruptio placentae may be at increased risk of Rh sensitization because they fail to receive Rh immunoglobulin (RhIG) or are given an inadequate dose. To evaluate the use of RhIG in this clinical situation, we studied 498 patients with hemorrhage from placenta previa or abruptio placentae treated at a large municipal hospital from 1975 to 1979. All 25 RhIG candidates received the product before their discharge from the hospital. This rate of RhIG use was equal to that for patients whose infants were delivered without these complications and significantly higher than that for patients with spontaneous abortion and ectopic pregnancy at the same hospital (P less than .05). Prompt administration of an adequate dose of RhIG to candidates with bleeding from placenta previa or abruptio placentae can further reduce Rh hemolytic disease.
前置胎盘或胎盘早剥导致产科出血的患者，由于未接受Rh免疫球蛋白（RhIG）或剂量不足，发生Rh致敏的风险可能会增加。为了评估RhIG在这种临床情况下的使用情况，我们研究了1975年至1979年在一家大型市立医院接受治疗的498例前置胎盘或胎盘早剥出血患者。所有25例符合使用RhIG条件的患者在出院前均接受了该产品治疗。这种RhIG的使用率与婴儿分娩时无这些并发症的患者相同，且显著高于同一家医院自然流产和异位妊娠患者的使用率（P<0.05）。对前置胎盘或胎盘早剥出血的符合条件患者及时给予足量的RhIG，可进一步降低Rh溶血病的发生。
